Sonali M. Vaidya

Sonali M. Vaidya

Auto-generated profile, based on publicly available information

Sonali M. Vaidya

Department: Pharmaceutical Biochemistry and Bioanalytics Institution: Pharmaceutical Institute University of Bonn, Address 1: An der Immenburg 4 Bonn Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in Analytica Chimica Acta
Verified
Journal Article
Open access
MHMarie-T. Hopp
Marie-T. Hopp
SVSonali M. Vaidya
Sonali M. Vaidya
KGKarina M. Grimmig
Karina M. Grimmig
LSLasse Johannes Strudthoff
Lasse Johannes Strudthoff
JCJohanna C. Clauser
Johanna C. Clauser
Diana ImhofDiana Imhof
Diana Imhof
Intravascular hemolysis is associated with massive release of hemoglobin and consequently labile heme into the blood, resulting in prothrombotic and proinflammatory events in patients. Though heme is well-known to participate in these adverse effects, it is not monitored. Instead, haptoglobin and hemoglobin serve as clinical biomarkers. The quantification of labile heme together with hemoglobin, however, should be considered in clinical diagnosis as well, to obtain a complete picture of the hemolytic state in patients. So far, quantification techniques for labile heme were not yet systematically analyzed and compared for their clinical application potential, especially in the presence of hemoglobin. Two commercial assays (Heme Assay Kit®, Hemin Assay Kit®) and five common approaches (pyridine hemochromogen assay, apo-horseradish peroxidase-based assay, UV/Vis spectroscopy, HPLC, mass spectrometry) were analyzed concerning their linearity, accuracy, and precision, as well as their ability to distinguish between hemoglobin-bound heme and labile heme. Further, techniques for the quantification of hemoglobin (Harboe method, SLS method, Hemastix®) were included to study their selectivity for hemoglobin and potential interference by the presence of labile heme. Both, indirect and direct approaches were suitable for the determination of a wide concentration of heme (∼0.02-45 μM) and hemoglobin (∼0.002-17 μM). A clear distinction between hemoglobin-bound heme and labile heme with one method was not possible. Thus, a novel combined approach is presented and applied to human and porcine plasma samples for the determination of hemoglobin and labile heme. Our results demonstrate the need to develop improved techniques to differentiate labile and protein-bound heme for early detection of intravascular hemolysis. Here, we present a novel strategy by combining two spectroscopic methods, which is most reliable as an easy-to-use tool for the determination of hemoglobin and heme levels in plasma samples for the diagnosis of intravascular hemolysis and in basic biomedical research.

20 January 2025 in ChemBioChem
Verified
Journal Article
Open access
SVSonali M. Vaidya
Sonali M. Vaidya
DRDhruv C. Rathod
Dhruv C. Rathod
ARAnuradha Ramoji
Anuradha Ramoji
UNUte Neugebauer
Ute Neugebauer
Diana ImhofDiana Imhof
Diana Imhof
Heme is involved in many critical processes in pathogenic bacteria as iron acquisition by these microorganisms is achieved by either direct uptake of heme or use of heme‐binding proteins called hemophores. Exploring the underlying mechanisms on a molecular level can open new avenues in understanding the host‐pathogen interactions. Any imbalance of the heme concentration has a direct impact on the bacterial growth and survival. Thus, heme‐regulated proteins that are involved in heme homeostasis poise to be promising targets for research. Similarly, naturally occurring compounds, including cysteine‐rich peptides from either plant secondary metabolites or venom toxins from vertebrates and invertebrates, have been studied for their therapeutic potential. NCR247 is such a cysteine‐rich peptide, known to be crucial for nitrogenase activity in M. truncatula and its symbiotic relation with S. meliloti . NCR247‐derived peptides were suggested to serve as high‐affinity heme‐binding molecules with remarkable heme‐capturing properties. A comprehensive biochemical and computational analysis of NCR247‐derived peptides, however, redefines their heme‐binding capacity and consequently their potential therapeutic role.